References
- 1
Kopple JF.
The phenomenon of altered risk factor patterns or reverse epidemiology in persons
with advanced chronic kidney failure.
Am J Clin Nutr.
2005;
81
1257-1266
- 2
Rathmann W, Haastert B, Herder C, Hauner H, Koenig W, Meisinger C, Holle R, Giani G.
Differential association of adiponectin with cardiovascular risk markers in men and
women? The KORA Survey 2000.
Int J Obes (Lond).
, epub ahead of print 2006 Nov 21
- 3
Herder C, Hauner H, Haastert B, Röhrig K, Koenig W, Kolb H, Müller-Scholze S, Thorand B,
Holle R, Rathmann W.
Hypoadiponectinemia and proinflammatory state: Two sides of the same coin? Results
from the Cooperative Health Research in the Region of Augsburg Survey 4 (KORA S4).
Diabetes Care.
2006;
29
1626-1631
- 4
Kistorp C, Faber J, Galatius S, Gustafsson F, Frystyk J, Flyvbjerg A, Hildebrandt P.
Plasma adiponectin, body mass index, and mortality in patients with chronic heart
failure.
Circulation.
2005;
112
1756-1762
- 5
George J, Patal S, Wexler D, Sharabi Y, Peleg E, Kamari Y, Grossman E, Sheps D, Keren G,
Roth A.
Circulating adiponectin levels predict outcome in patients with congestive heart failure.
Heart.
2006;
92
1420-1424
- 6
Cavusoglu E, Ruwende C, Chopra V, Yanamadala S, Eng C, Clark LT, Pinsky DJ, Marmur JD.
Adiponectin is an independent predictor of all-cause mortality, cardiac mortality,
and myocardial infarction in patients presenting with chest pain.
Eur Heart J.
2006;
27
2300-2309
- 7
Pilz S, Mangge H, Wellnitz B, Seelhorst U, Winkelmann BR, Tiran B, Boehm BO, März W.
Adiponectin and mortality in patients undergoing coronary angiography.
J Clin Endocrinol Metab.
2006;
91
4277-4286
- 8
Menon V, Li L, Wang X, Green T, Balakrishnan V, Madero M, Pereira AA, Beck GJ, Kusek JW,
Collins AJ, Levey AS, Sarnak MJ.
Adiponectin and mortality in patients with chronic kidney disease.
J Am Soc Nephrol.
2006;
17
2599-2606
- 9
Hadjadj S, Aubert R, Fumeron F, Pean F, Tichet J, Roussel R, Marre M. SURGENE and
DESIR study groups .
Increased plasma adiponectin concentrations are associated with microangiopathy in
type 1 diabetic subjects.
Diabetologia.
2005;
48
1088-1092
- 10
Tietge UJF, Böker KHW, Manns MP, Bahr MJ.
Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced
liver function and altered hepatic hemodynamics.
Am J Physiol Endocrinol Metab.
2004;
287
E82-E89
- 11
Otero M, Lago R, Gomez R, Dieguez C, Gómez-Reino JJ, Gualillo O.
Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and
visfatin in patients with rheumatoid arthritis.
Ann Rheum Dis.
2006;
65
1198-1201
- 12
Karmiris K, Koutroubakis IE, Xidakis C, Polychronaki M, Voudouri T, Kouroumalis EA.
Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel
disease.
Inflamm Bowel Dis.
2006;
12
100-105
- 13
Sada KE, Yamasaki Y, Maruyama M, Sugiyama H, Yamamura M, Maeshima Y, Makino H.
Altered levels of adipocytokines in association with insulin resistance in patients
with systemic lupus erythematosus.
J Rheumatol.
2006;
33
1545-1552
- 14
Lara-Castro C, Luo N, Wallace P, Klein RL, Garvey WT.
Adiponectin multimeric complexes and the metabolic syndrome trait cluster.
Diabetes.
2006;
55
249-259
- 15
Komaba H, Igaki N, Goto S, Yokota K, Doi H, Takemoto T, Kohno M, Hirosue Y, Goto T.
Increased serum high-molecular-weight complex of adiponectin in type 2 diabetic patients
with impaired renal function.
Am J Nephrol.
2006;
476-482
Correspondence
W. Rathmann
MSPH (USA)
Institute of Biometrics and Epidemiology
German Diabetes Center
Auf'm Hennekamp 65
40225 Düsseldorf
Germany
Phone: +4921133 82 663
Fax: +4921133 82 677
Email: rathmann@ddz.uni-duesseldorf.de
